Citigroup Lowers Axalta Coating Systems Stock Price Target

Analysts cite concerns about the specialty chemicals company's outlook

Apr. 1, 2026 at 8:54pm

Got story updates? Submit your updates here. ›

Citigroup analysts have reduced their price target for Axalta Coating Systems (NYSE:AXTA) stock from $45 to $42, while maintaining a 'buy' rating on the company. The analysts cited a more pessimistic forecast for the specialty chemicals firm in their latest report.

Why it matters

Axalta Coating Systems is a major player in the specialty chemicals industry, providing coatings for the automotive, industrial, and architectural sectors. Citigroup's downgrade of the stock price target could signal broader concerns about the company's performance and the economic outlook for its key markets.

The details

In their report, Citigroup analysts lowered Axalta's price target from $45 to $42 per share, while reiterating a 'buy' rating on the stock. The analysts noted that the revised target still represents a potential upside of nearly 52% from the company's previous closing price. Axalta Coating Systems has been the subject of several other research reports in recent months, with a mix of 'buy' and 'hold' ratings from various firms.

  • Citigroup released its updated report on Axalta Coating Systems on April 1, 2026.

The players

Axalta Coating Systems

A global leader in the development, manufacture, and sale of liquid and powder coatings, serving the automotive, industrial, and architectural sectors.

Citigroup

A major global investment bank and financial services corporation that provides research coverage and analysis on various publicly traded companies.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Axalta Coating Systems' upcoming earnings report and guidance to see if the company's performance aligns with Citigroup's more pessimistic outlook.

The takeaway

Citigroup's downgrade of Axalta Coating Systems' stock price target reflects broader concerns about the company's outlook and the economic conditions facing its key markets. This could signal potential challenges ahead for the specialty chemicals firm, despite its 'buy' rating.